Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
TROP2
Description:
TROP2 is a cell-surface protein encoded by the human TACSTD2 gene and studied as a cancer marker and therapeutic target.
Related topics:
Breast Cancer Treatment Studies (10%),
Monoclonal and Polyclonal Antibodies Research (9%),
Lung Cancer Treatments and Mutations (8%)
Wikidata ID:
wiki/Q18028738
OpenAlex ID:
keywords/trop2
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
2021
·
Aditya Bardia
, Sara A. Hurvitz
, et al.
·
New England Journal of Medicine
·
1,863
PDF
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
2016
·
Ju X
, Jiao X
, et al.
·
Research Explorer (The University of Manchester)
·
1,064
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
2019
·
Aditya Bardia
, Ingrid A. Mayer
, et al.
·
New England Journal of Medicine
·
907
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
2021
·
Scott T. Tagawa
, Arjun V. Balar
, et al.
·
Journal of Clinical Oncology
·
563
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
2015
·
David M. Goldenberg
, Thomas M. Cardillo
, et al.
·
Oncotarget
·
521
PDF
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
2021
·
Paolo Tarantino
, Roberto Carmagnani Pestana
, et al.
·
CA A Cancer Journal for Clinicians
·
451
PDF
Trop2 and its overexpression in cancers: regulation and clinical/ therapeutic implications
2014
·
Anna Shvartsur
, Benjamin Bonavida
·
Genes & Cancer
·
444
PDF
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
2021
·
A. Bardia
, W.A. Messersmith
, et al.
·
Annals of Oncology
·
434
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
2017
·
Aditya Bardia
, Ingrid A. Mayer
, et al.
·
Journal of Clinical Oncology
·
431
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells
2021
·
Daisuke Okajima
, Satoru Yasuda
, et al.
·
Molecular Cancer Therapeutics
·
383
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
2015
·
Alexander N. Starodub
, Allyson J. Ocean
, et al.
·
Clinical Cancer Research
·
359
Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics
2008
·
Andrew S. Goldstein
, Devon A. Lawson
, et al.
·
Proceedings of the National Academy of Sciences
·
353
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
2022
·
Hope S. Rugo
, Aditya Bardia
, et al.
·
Journal of Clinical Oncology
·
344
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
2018
·
David M. Goldenberg
, Rhona Stein
, et al.
·
Oncotarget
·
344
PDF
Upregulation of Trop-2 quantitatively stimulates human cancer growth
2012
·
M Trerotola
, P Cantanelli
, et al.
·
Oncogene
·
341
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
2015
·
Thomas M. Cardillo
, Serengulam V. Govindan
, et al.
·
Bioconjugate Chemistry
·
317
Human trophoblast cell-surface antigens defined by monoclonal antibodies.
1981
·
M Lipinski
, D R Parks
, et al.
·
Proceedings of the National Academy of Sciences
·
315
Sacituzumab Govitecan: First Approval
2020
·
Yahiya Y. Syed
·
Drugs
·
310
PDF
Identification of Lgr5-Independent Spheroid-Generating Progenitors of the Mouse Fetal Intestinal Epithelium
2013
·
Roxana C. Mustata
, Gabriela Vasile
, et al.
·
Cell Reports
·
296
PDF
Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues: Potential Implications as a Cancer Therapeutic Target
2011
·
Lara P. Stepan
, Esther S. Trueblood
, et al.
·
Journal of Histochemistry & Cytochemistry
·
291
Potential hepatic stem cells reside in EpCAM+ cells of normal and injured mouse liver
2009
·
Mayuko Okabe
, Yuko Tsukahara
, et al.
·
Development
·
290
Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer
2021
·
James T. Coates
, Sheng Sun
, et al.
·
Cancer Discovery
·
274
PDF
Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma
2007
·
Barbara A. Frederick
, Barbara A. Helfrich
, et al.
·
Molecular Cancer Therapeutics
·
272
Antibody–drug conjugates in solid tumors: a look into novel targets
2021
·
Carmen Criscitiello
, Stefania Morganti
, et al.
·
Journal of Hematology & Oncology
·
266
PDF
Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics
2017
·
Allyson J. Ocean
, Alexander N. Starodub
, et al.
·
Cancer
·
252
PDF
Show more works
View as search
Works count:
3,129
Citation count:
42,990
Year
Topic
Type